Urban Peak Shelter and University of Denver
Denver, Colorado, 80223, United States
NCT Number: NCT04183400
The SAFE study examines the effects of brief mindfulness-based cognitive-behavioral intervention aimed at improving risk-related attention skills (risk detection, problem solving, assertiveness, and help seeking) in order to reduce substance use and victimization among young people (ages 18-21) experiencing homelessness.
Looking for future studies?
Notify Me18 year–21 year
All sexes
Interventional
Not applicable
Denver, Colorado, 80223, United States
Youth (ages 18-21) living at a local youth shelter will be recruited and randomly assigned to receive the SAFE intervention (plus usual case management) or to receive usual case management only. Those assigned to SAFE will receive 12 mindfulness-based, cognitive-behavioral modules through a 3-day intensive group intervention provided by an agency intern and a hired project staff member. The intervention uses mindfulness-based cognitive-behavioral approaches to augment youth attention to risk-related processes, including risk detection, problem solving, assertiveness, and help seeking skills. It is hypothesized the intervention will result in reduced substance use and victimization and that these effects will be explained, at least in part, by improved risk-related attention skills (risk detection, problem solving, assertiveness, and help seeking skills). Post baseline interview, participants will be randomly assigned and will participate in a posttest interview (1 week post baseline) and follow up interviews at 6-weeks, 3-months, and 6-months post baseline interview.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
As measured by the KSADS (a semi-structured diagnostic interview administered by trained interviewers at baseline):
SAFE is a mindfulness-based cognitive-behavioral intervention that aims to build risk-related attention skills.
Time frame: Follow up at 6-weeks post baseline interview
The Substance use domain of the Addiction Severity Index, 5th edition will be used to assess the frequency, type and amount of substance use in the past 30 days. This domain will be adapted to add smoking tobacco to the list of substances.
Time frame: Follow up at 3-months post baseline interview
The Substance use domain of the Addiction Severity Index, 5th edition will be used to assess the frequency, type and amount of substance use in the past 30 days. This domain will be adapted to add smoking tobacco to the list of substances.
Time frame: Follow up at 6-months post baseline interview
The Substance use domain of the Addiction Severity Index, 5th edition will be used to assess the frequency, type and amount of substance use in the past 30 days. This domain will be adapted to add smoking tobacco to the list of substances.
Time frame: Follow up at 6-weeks post baseline interview
The Juvenile Victimization Questionnaire (JVQ) will be used to asses exposure to a range of types of victimization.
Time frame: Follow up at 3-months post baseline interview
The Juvenile Victimization Questionnaire (JVQ) will be used to asses exposure to a range of types of victimization.
Time frame: Follow up at 6-months post baseline interview
The Juvenile Victimization Questionnaire (JVQ) will be used to asses exposure to a range of types of victimization.
Time frame: Follow up at 6-weeks, 3-months, and 6-months post baseline interview, controlling for baseline
The Mini International Neuropsychiatry Interview (MINI) will be used to assess a count of the number of substance use symptoms experienced.
Time frame: Follow up at 6-weeks, 3-months, and 6-months post baseline interview, controlling for baseline
The Mini International Neuropsychiatry Interview (MINI) will be used to assess a whether the participant meets DSM diagnostic criteria for a substance use disorder
Time frame: Follow up at 1-week, 6-weeks, and 3-months post baseline interview, controlling for baseline
Risk detection will be assessed a set of researcher-developed Risk Vignettes that describe characters in risk situations and ask participants to identify risk cues present; measure will be proportion of risk cues identified among those present in the vignettes administered
Time frame: Follow up at 1-week, 6-weeks, and 3-months post baseline interview, controlling for baseline
Help seeking intentions will be assessed with a modified version of the General Help Seeking Questionnaire which assesses intentions to seek help from different sources for different problems. The original scale asks about seeking help for emotional problems and suicidal thoughts; our version was modified to ask about help seeking related to safety issues and substance use. Higher scores indicate greater help seeking thus a more positive outcome.
Time frame: Follow up at 1-week, 6-weeks, and 3-months post baseline interview, controlling for baseline
Help seeking behaviors will be assessed by items from the Help Seeking Behaviors scale which ask how often youth actually sought help fro different sources of help for substance and for safety.
Time frame: Follow up at 1-week, 6-weeks, and 3-months post baseline interview, controlling for baseline
Assertiveness will be assessed using the Assertion Inventory which asks how often participants engage in assertive behaviors across three domains: substance use, general, and social situations
University of Denver
Other
Acronym: SAFE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04873401
COVID-19, Chemically-Induced Disorders
New York, United States
View Trial DetailsNCT05378399
Adherence, Medication, Adherence, Treatment
Boston, Massachusetts, United States
View Trial DetailsNCT05286879
Behavior, Chemically-Induced Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT06008990
Buprenorphine Dependence, Chemically-Induced Disorders
Indianapolis, Indiana, United States
View Trial Details